Nebius Secures $775 Million in First Secured Debt Financing to Fuel AI Cloud Expansion
Strong demand from MUFG-led banks supports $40B+ revenue backlog with Microsoft and Meta.
NOTRELOAD AI
Kalaris Reinforces TH103’s Potential in Wet AMD Ahead of 2027 Catalyst
Kalaris reports 6-month follow-up data from 20 patients in TH103 Phase 1a trial. 29% of treatment-naïve patients remained injection-free for 6 months. Phase 1b/2 data expected H1 2027.
Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
REGENXBIO Prices $100 Million Public Offering to Extend Cash Runway into 2028
Proceeds will support late-stage AAV gene therapy programs and extend cash runway to 2028.
AST SpaceMobile Gets B. Riley Buy Upgrade as $1B Convertible Deal Funds Satellite Expansion
B. Riley sees upside after a 44% drop and continues to back AST SpaceMobile’s satellite broadband growth plans.
GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).